Interstitial lung involvement in rheumatoid arthritis

Rheumatoid arthritis (RA) is a systemic autoimmune rheumatic disease of unknown etiology, characterized by chronic erosive arthritis and extraarticular manifestations. Pulmonary involvement is one of the common extraarticular manifestations of RA and may show itself as bronchial tree lesions, rheuma...

Full description

Saved in:
Bibliographic Details
Main Authors: David Vladimirovich Bestaev, T. D. Bestaeva
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2014-12-01
Series:Современная ревматология
Subjects:
Online Access:https://mrj.ima-press.net/mrj/article/view/575
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839574190822260736
author David Vladimirovich Bestaev
T. D. Bestaeva
author_facet David Vladimirovich Bestaev
T. D. Bestaeva
author_sort David Vladimirovich Bestaev
collection DOAJ
description Rheumatoid arthritis (RA) is a systemic autoimmune rheumatic disease of unknown etiology, characterized by chronic erosive arthritis and extraarticular manifestations. Pulmonary involvement is one of the common extraarticular manifestations of RA and may show itself as bronchial tree lesions, rheumatoid nodules, Caplan's syndrome, and lesions in the pleura or pulmonary interstitium (interstitial lung involvement (ILI)). High-resolution computed tomography allows the diagnosis of ILI in RA in nearly 70% of cases although the incidence of ILI may be lower (4 to 30%) depending on diagnostic methods and patient selection criteria. There are several histopathological types of ILI, the differential diagnosis of which can be troublesome. Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia are major types of RA-associated ILI. UIP-pattern ILI has a more severe course than ILI with other histological patterns. The clinical presentation of ILI may be complicated by the likely toxic effect of a number of disease-modifying antirheumatic drugs (DMARDs) used to treat RA, such as methotrexate and leflunomide, and biological agents (BAs), tumor necrosis factor-α (TNF-α) inhibitors. The pathogenesis of pulmonary involvement in RA and the role of synthetic DMARDs and BAs in the development of ILI call for further investigations.An extraarticular manifestation, such as ILI, affects the choice of treatment policy in patients with RA.The relevance of a study of ILI is beyond question. The paper discusses the state-of-the-art of investigations in this area.
format Article
id doaj-art-0221d5b5d0c942f19f975b5799d10802
institution Matheson Library
issn 1996-7012
2310-158X
language Russian
publishDate 2014-12-01
publisher IMA-PRESS LLC
record_format Article
series Современная ревматология
spelling doaj-art-0221d5b5d0c942f19f975b5799d108022025-08-04T14:00:32ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2014-12-0184485310.14412/1996-7012-2014-4-48-531876Interstitial lung involvement in rheumatoid arthritisDavid Vladimirovich Bestaev0T. D. Bestaeva1V.A. Nasonova Research Institute of RheumatologyNorth-Ossetian State Medical Academy, Ministry of Health of RussiaRheumatoid arthritis (RA) is a systemic autoimmune rheumatic disease of unknown etiology, characterized by chronic erosive arthritis and extraarticular manifestations. Pulmonary involvement is one of the common extraarticular manifestations of RA and may show itself as bronchial tree lesions, rheumatoid nodules, Caplan's syndrome, and lesions in the pleura or pulmonary interstitium (interstitial lung involvement (ILI)). High-resolution computed tomography allows the diagnosis of ILI in RA in nearly 70% of cases although the incidence of ILI may be lower (4 to 30%) depending on diagnostic methods and patient selection criteria. There are several histopathological types of ILI, the differential diagnosis of which can be troublesome. Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia are major types of RA-associated ILI. UIP-pattern ILI has a more severe course than ILI with other histological patterns. The clinical presentation of ILI may be complicated by the likely toxic effect of a number of disease-modifying antirheumatic drugs (DMARDs) used to treat RA, such as methotrexate and leflunomide, and biological agents (BAs), tumor necrosis factor-α (TNF-α) inhibitors. The pathogenesis of pulmonary involvement in RA and the role of synthetic DMARDs and BAs in the development of ILI call for further investigations.An extraarticular manifestation, such as ILI, affects the choice of treatment policy in patients with RA.The relevance of a study of ILI is beyond question. The paper discusses the state-of-the-art of investigations in this area.https://mrj.ima-press.net/mrj/article/view/575rheumatoid arthritisinterstitial lung involvement
spellingShingle David Vladimirovich Bestaev
T. D. Bestaeva
Interstitial lung involvement in rheumatoid arthritis
Современная ревматология
rheumatoid arthritis
interstitial lung involvement
title Interstitial lung involvement in rheumatoid arthritis
title_full Interstitial lung involvement in rheumatoid arthritis
title_fullStr Interstitial lung involvement in rheumatoid arthritis
title_full_unstemmed Interstitial lung involvement in rheumatoid arthritis
title_short Interstitial lung involvement in rheumatoid arthritis
title_sort interstitial lung involvement in rheumatoid arthritis
topic rheumatoid arthritis
interstitial lung involvement
url https://mrj.ima-press.net/mrj/article/view/575
work_keys_str_mv AT davidvladimirovichbestaev interstitiallunginvolvementinrheumatoidarthritis
AT tdbestaeva interstitiallunginvolvementinrheumatoidarthritis